Are Insulin Analogues Detemir or Glulisine Used Preferentially in Overweight/Obese Subjects? A German Multicentre Analysis of 38560 Type 2 Diabetic Patients from the DPV Registry

Bohn, B.; Scheuing, N.; Jehle, P. M.; Laubner, K.; Born, B.; Merger, S.; Hummel, M.; Krakow, D.; Voll, A.; Zimmermann, A.; Zimny, S.; Holl, Reinhard; DPV APV Initiatives; German BMBF Competence Networks Di

Erstveröffentlichung

2014

Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors

Bohn, B.

Scheuing, N.

Jehle, P. M.

Laubner, K.

Born, B.

et al.

Faculties

Medizinische Fakultät

Institutions

Institut für Epidemiologie und Medizinische Biometrie
UKU. Klinik für Innere Medizin I

Published in

Experimental and Clinical Endocrinology & Diabetes ; 122 (2014), 10. - S. 602-607. - ISSN 0947-7349. - eISSN 1439-3646

Link to publication

https://dx.doi.org/10.1055/s-0034-1383646

Keywords

insulin analogues; detemir; glulisine; type 2 diabetes; body mass index; LESS WEIGHT-GAIN; NPH INSULIN; FASTER ONSET; PHARMACOKINETICS; PHARMACODYNAMICS; METAANALYSIS; GLARGINE; THERAPY; ASPART; RISK

Dewey Decimal Group

DDC 610 / Medicine & health

Metadata

Show full item record